Patents by Inventor Shelley Sims Belouski
Shelley Sims Belouski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9238691Abstract: Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, preferably human CCR2, and that may inhibit CCR2. The present antibodies may bind to the first and/or second extracellular loops of CCR2. Isolated heavy and light chains derived from the antibodies and nucleic acid molecules encoding the antibodies and chains are provided. Methods of making and using the anti-CCR2 antibodies or antigen-binding portions, and compositions comprising these antibodies or antigen-binding portions, including compositions for diagnosis and treatment, are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light chains that comprise the human anti-CCR2 antibodies or antigen-binding portions thereof.Type: GrantFiled: April 3, 2014Date of Patent: January 19, 2016Assignees: Pfizer Inc., Amgen Fremont Inc.Inventors: Ronald P. Gladue, Bradley T. Keller, Shinji Ogawa, Arvind Rajpal, Laurie A. Tylaska, Shelley Sims Belouski, Larry L. Green, Meina Liang
-
Patent number: 9221915Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like, kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: GrantFiled: October 26, 2011Date of Patent: December 29, 2015Assignees: Pfizer Inc., Amgen Fremont Inc.Inventors: Shelley Sims Belouski, Sirid-Aimée Kellerman, Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
-
Publication number: 20140342450Abstract: Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, preferably human CCR2, and that may inhibit CCR2. The present antibodies may bind to the first and/or second extracellular loops of CCR2. Isolated heavy and light chains derived from the antibodies and nucleic acid molecules encoding the antibodies and chains are provided. Methods of making and using the anti-CCR2 antibodies or antigen-binding portions, and compositions comprising these antibodies or antigen-binding portions, including compositions for diagnosis and treatment, are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light chains that comprise the human anti-CCR2 antibodies or antigen-binding portions thereof.Type: ApplicationFiled: April 3, 2014Publication date: November 20, 2014Applicants: Amgen Fremont Inc., Pfizer Inc.Inventors: Ronald P. Gladue, Bradley T. Keller, Shinji Ogawa, Arvind Rajpal, Laurie A. Tylaska, Shelley Sims Belouski, Larry L. Green, Meina L. Liang
-
Patent number: 8710191Abstract: Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CCR2 antibodies or antigen binding portions thereof.Type: GrantFiled: August 17, 2009Date of Patent: April 29, 2014Assignees: Pfizer Inc., Amgen Fremont Inc.Inventors: Ronald P. Gladue, Bradley T. Keller, Shinji Ogawa, Arvind Rajpal, Laurie A. Tylaska, Shelley Sims Belouski, Larry L. Green, Meina Liang
-
Publication number: 20120052074Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like, kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: ApplicationFiled: October 26, 2011Publication date: March 1, 2012Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: Shelley Sims Belouski, Sirid-Aimée Kellerman, Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
-
Publication number: 20110274696Abstract: Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided.Type: ApplicationFiled: August 17, 2009Publication date: November 10, 2011Applicants: AMGEN FREMONT INC., PFIZER INC.Inventors: Ronald P. Gladue, Bradley T. Keller, Shinji Ogawa, Arvind Rajpal, Laurie A. Tylaska, Shelley Sims Belouski, Larry L. Green, Meina Liang
-
Publication number: 20100197005Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: ApplicationFiled: March 12, 2009Publication date: August 5, 2010Applicants: Amgen Fremont Inc., Pfizer Inc.Inventors: Shelley Sims Belouski, Sirid-Aimee Kellermann, Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang
-
Patent number: 7537762Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular domain (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.Type: GrantFiled: September 6, 2006Date of Patent: May 26, 2009Assignees: Amgen Fremont, Inc., Pfizer Inc.Inventors: Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Shelley Sims Belouski, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, Sirid Aimee Kellerman, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang